Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia
Effect of Nigella Sativa on Blood Lipids as an add-on Therapy in Atorvastatin Treated Hyperlipidaemic Patients. A Randomized Controlled Trial
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
84 participants
Aug 24, 2023
INTERVENTIONAL
Conditions
Summary
This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of Nigella Sativa in 84 Hyperlipidaemic patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either Nigella Sativa 500 mg capsule daily or placebo capsule identical to Nigella Sativa twice daily for 8 weeks. Evaluation of lipid profile, SGPT, S.Creatinine will be before and after 8 weeks of intervention. Nigella Sativa related adverse events will be identified. Study outcome will establish safety and efficacy of Nigella Sativa in atorvastatin treated hyperlipidaemic patients
Eligibility
Inclusion Criteria8
- Newly diagnosed hyperlipidaemic patient.
- Both male and female
- Hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension
- Diagnostic criteria for dyslipidemic patients
- Total cholesterol 200mg/dl
- LDL-C 140mg/dl
- Triglyceride 150mg/dl
- HDL <40mg/dl
Exclusion Criteria5
- Patients with renal impairment
- Patients with active liver disease
- Patients having history of hypersensitivity on any member of statins
- Pregnant woman.
- lactating mother
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nigella Sativa capsule 500mg twice daily for 8 weeks
Oral placebo identical to astaxanthin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06422650